0001104659-24-008787.txt : 20240131 0001104659-24-008787.hdr.sgml : 20240131 20240131160516 ACCESSION NUMBER: 0001104659-24-008787 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240131 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980505495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37852 FILM NUMBER: 24582888 BUSINESS ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 BUSINESS PHONE: (510) 474-0170 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 8-K 1 tm244678d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 31, 2024

PROTAGONIST THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37852		98-0505495
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Protagonist Therapeutics, Inc.

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

(510) 474-0170

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001		PTGX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement

Collaboration and License Agreement

On January 31, 2024, Protagonist Therapeutics, Inc. (the “Company”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”) with Takeda Pharmaceuticals USA, Inc. (“Takeda”) for the development, manufacture and commercialization of the Company’s rusfertide product candidate (“Rusfertide”) and other specified second-generation injectable hepcidin mimetic compounds (the “Licensed Products”). The Collaboration Agreement will become effective (the “Effective Date”) upon the receipt of clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Collaboration and Licenses. The Company and Takeda have agreed that the parties will, as further described below, jointly develop and commercialize the Licensed Products in the United States (the “Profit-Share Territory”) and that Takeda solely and exclusively will develop and commercialize the Licensed Products in all other countries (the “Takeda Territory”). Each of the Company and Takeda is obligated to use commercially reasonable efforts to develop and commercialize at least one Licensed Product in the Profit-Share Territory, and Takeda is also obligated to use commercially reasonable efforts to develop and commercialize at least one Licensed Product in major regions of the Takeda Territory.

The Company and Takeda have agreed to share costs of the development, manufacture and commercialization activities for the Licensed Products under the Collaboration Agreement in the Profit-Share Territory, provided that (i) the Company will lead, and will be responsible for its costs associated with, completion of the ongoing Phase 3 VERIFY program evaluating Rusfertide for the treatment of Polycythemia Vera (the “VERIFY Program”); (ii) Takeda will lead, and will be responsible for its costs associated with, pre-commercialization activities related to Rusfertide in the Profit-Share Territory, and (iii) Takeda will lead commercialization of rusfertide globally, with Protagonist holding an option to co-detail in the U.S. Takeda is solely responsible for all costs for the development, manufacture and commercialization activities under the Collaboration Agreement in the Takeda Territory, and will have sole responsibility and decision-making authority with respect to such activities in the Takeda Territory.

The Company has agreed to grant to Takeda a non-transferable, sublicensable, except for certain specified exceptions, license to certain intellectual property of the Company as needed to perform the activities under the Collaboration Agreement. Such license is co-exclusive with the Company in the Profit-Share Territory and exclusive, even as to the Company, in the Takeda Territory, subject to certain retained rights to allow the Company to exercise its rights and perform its obligations under the Collaboration Agreement.

Financial Terms; Opt-out Rights.

Upfront Payment; Profit Share; Booking of Revenues. Under the terms of the Collaboration Agreement, Takeda has agreed to pay the Company an upfront payment of $300 million within 30 days after the Effective Date. For so long as a Licensed Product is being sold in the Profit-Share Territory, the Company and Takeda will share in all operating profits and losses arising from such Licensed Product in the Profit-Share Territory (50 percent to the Company and 50 percent to Takeda) as further defined in the Collaboration Agreement. The Collaboration Agreement provides that Takeda will book sales of Licensed Products globally.

Royalties. Takeda has agreed to pay the Company tiered royalties of 10% – 17% on net sales of Licensed Products in the Takeda Territory. If the Company has exercised an Opt-out Right (as defined below), Takeda has agreed to pay the Company royalties of 14% – 29% on worldwide net sales of Licensed Products with respect to which the Company has exercised an Opt-out Right. Royalty payments may be reduced in certain specified circumstances.

Milestone Payments; Opt-out Payment. The Collaboration Agreement provides for aggregate development, regulatory and commercial milestone payments from Takeda to the Company for Licensed Products of (i) up to $330 million if the Company does not exercise an Opt-out Right and remains in the 50:50 profit- and loss-sharing arrangement in the Profit-Share Territory; and (ii) up to $975 million if the Company exercises the Full Opt-out Right (as defined below). Milestone payments as to Licensed Products other than Rusfertide may be reduced in certain specified circumstances.

In addition to the milestone payments described above, in the event the Company exercises the Full Opt-out Right during the Initial Opt-out Period (as defined below), the Company will receive: (a) a $200 million payment following its exercise of the Full Opt-out Right, and (b) an additional $200 million payment following FDA approval of the New Drug Application for Rusfertide for polycythemia vera (together, the “Opt-out Payment”).

Opt-out Rights. The Company will have the right to opt-out entirely of profit- and loss-sharing in the Profit-Share Territory as to all Licensed Products (the “Full Opt-out Right”) during the 90-day period beginning 120 days after filing of a New Drug Application with the United States Food and Drug Administration for Rusfertide for Polycythemia Vera (the “Initial Opt-out Period”); and (ii) for convenience without receipt of the Opt-out Payment (generally following the Initial Opt-out Period). In addition, if the Company does not exercise the Full Opt-out Right, the Company may opt-out of profit- and loss-sharing in the Profit-Share Territory as to Licensed Products other than Rusfertide on a Licensed Product-by-Licensed Product basis (each, a “Partial Opt-out Right” and either the Full Opt-out Right or a Partial Opt-out right being an “Opt-out Right”). Following the Company’s exercise of an Opt-out Right, the Company has agreed to transition to Takeda applicable development and commercial activities, and Takeda has agreed to assume sole operational and financial responsibility for such activities.

Governance. The activities of the parties for the Profit-Share Territory are to be conducted pursuant to joint development plans and joint commercialization plans, on a Licensed Product-by-Licensed Product basis, and overseen by a joint steering committee (the “JSC”) and various subcommittees, including a Joint Commercialization Committee and a Joint Development Committee. The JSC shall be composed of an equal number of representatives from each of the Company and Takeda.

Exclusivity; Right of First Negotiation. During the term of the Collaboration Agreement, neither party nor any of its respective affiliates is permitted outside of the Collaboration Agreement to directly or indirectly develop, manufacture, or commercialize injectable hepcidin mimetic products beyond agreed-upon stages of development (pre-clinical in vitro research activities in the case of the Company, and up to Phase 2b clinical development in the case of Takeda, respectively are permitted). In addition, the Company has granted to Takeda a 120-day right of first negotiation with respect to other Company products in the hepcidin pathway.

Termination. Unless earlier terminated, the Collaboration Agreement expires on a Licensed Product-by-Licensed Product and country-by-country basis on the later of (a) in the Takeda Territory, the expiration of the royalty term for such Licensed Product in such country or (b) in the Profit-Share Territory, until the parties agree to permanently stop commercializing such Licensed Product. Takeda may terminate the Collaboration Agreement for convenience in its entirety or as to a major region by providing advance written notice following the earliest of (i) the receipt of Phase 3 data with respect to the VERIFY Program, (ii) the third anniversary of the Effective Date or (iii) upon the occurrence of certain specified adverse events related to the clinical development of Rusfertide. Either party may terminate the Collaboration Agreement in its entirety (A) in the event of a material breach by the other party, subject to a cure period and (B) in the event of the insolvency of the other party, in each case subject to specified conditions.

The foregoing description of the terms of the Collaboration Agreement is qualified in its entirety by reference to the full text of the Collaboration Agreement, a copy of which the Company intends to file with the U.S. Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Protagonist Therapeutics, Inc.

Dated: January 31, 2024

	By:	/s/ Asif Ali
		Asif Ali
		Chief Financial Officer

EX-101.SCH 2 ptgx-20240131.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ptgx-20240131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 ptgx-20240131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 31, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 31, 2024
Entity File Number	001-37852
Entity Registrant Name	PROTAGONIST THERAPEUTICS, INC.
Entity Central Index Key	0001377121
Entity Tax Identification Number	98-0505495
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7707 Gateway Blvd.
Entity Address, Address Line Two	Suite 140
Entity Address, City or Town	Newark
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94560-1160
City Area Code	510
Local Phone Number	474-0170
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.00001
Trading Symbol	PTGX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://protagonist-inc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ptgx-20240131.xsd ptgx-20240131_lab.xml ptgx-20240131_pre.xml tm244678d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm244678d1_8k.htm": { "nsprefix": "ptgx", "nsuri": "http://protagonist-inc.com/20240131", "dts": { "schema": { "local": [ "ptgx-20240131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ptgx-20240131_lab.xml" ] }, "presentationLink": { "local": [ "ptgx-20240131_pre.xml" ] }, "inline": { "local": [ "tm244678d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://protagonist-inc.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm244678d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm244678d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-24-008787-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-008787-xbrl.zip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end XML 15 tm244678d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001377121 2024-01-31 2024-01-31 iso4217:USD shares iso4217:USD shares false 0001377121 8-K 2024-01-31 PROTAGONIST THERAPEUTICS, INC. DE 001-37852 98-0505495 7707 Gateway Blvd. Suite 140 Newark CA 94560-1160 510 474-0170 false false false false Common Stock, par value $0.00001 PTGX NASDAQ false